HC Wainwright & Co. Maintains Neutral on Lyra Therapeutics, Raises Price Target to $16

Benzinga · 5d ago
HC Wainwright & Co. analyst Matthew Caufield maintains Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and raises the price target from $2 to $16.